AUREOMYCIN Drug Patent Profile
✉ Email this page to a colleague
When do Aureomycin patents expire, and when can generic versions of Aureomycin launch?
Aureomycin is a drug marketed by Lederle and is included in one NDA.
The generic ingredient in AUREOMYCIN is chlortetracycline hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the chlortetracycline hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AUREOMYCIN?
- What are the global sales for AUREOMYCIN?
- What is Average Wholesale Price for AUREOMYCIN?
Summary for AUREOMYCIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 53 |
| Patent Applications: | 4,663 |
| DailyMed Link: | AUREOMYCIN at DailyMed |
US Patents and Regulatory Information for AUREOMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lederle | AUREOMYCIN | chlortetracycline hydrochloride | OINTMENT;OPHTHALMIC | 050404-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
